Kite Pharma (KITE) volatility at 104 into lymphoma drug trial meets primary endpoint

September 27, 2016 6:10 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Kite Pharma (NASDAQ: KITE) is recently up $7.52 to $62.50 in the premarket after the cancer researcher reported data from an early analysis of its lead drug candidate KTE-C19, which met its goal of meaningfully shrinking tumors. Option implied volatility index mean is at 104, compared to its 52-week range of 51 to 117, according to Livevol.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Options, Trader Talk

Related Entities


Add Your Comment